5,749 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Marex Group plc

Marex Group plc acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 5,749 shares of the specialty pharmaceutical company’s stock, valued at approximately $610,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SVB Wealth LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth approximately $36,000. Hantz Financial Services Inc. lifted its stake in Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 297 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 137 shares during the last quarter. Brooklyn Investment Group boosted its holdings in shares of Jazz Pharmaceuticals by 411.1% in the 1st quarter. Brooklyn Investment Group now owns 552 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 444 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at $90,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

JAZZ has been the subject of several recent analyst reports. JPMorgan Chase & Co. dropped their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Piper Sandler reissued an “overweight” rating and issued a $219.00 target price (up previously from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday. UBS Group restated a “neutral” rating and issued a $188.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Morgan Stanley upped their price objective on shares of Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a research report on Monday, November 17th. Finally, Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $200.47.

Jazz Pharmaceuticals Stock Up 1.6%

NASDAQ:JAZZ opened at $167.50 on Monday. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The company has a market cap of $10.18 billion, a PE ratio of -27.59, a P/E/G ratio of 3.77 and a beta of 0.30. The firm’s 50 day simple moving average is $150.93 and its 200 day simple moving average is $129.40.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $177.78, for a total value of $607,118.70. Following the sale, the director owned 20,449 shares of the company’s stock, valued at $3,635,423.22. The trade was a 14.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Rick E. Winningham sold 5,500 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total value of $994,730.00. Following the transaction, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. This represents a 38.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 129,291 shares of company stock valued at $22,745,410 in the last quarter. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.